118 related articles for article (PubMed ID: 32519403)
1. C1188D mutation abolishes specific recognition between MLL1-CXXC domain and CpG site by inducing conformational switch of flexible N-terminal.
Chen J; Qi Y; Duan Y; Duan M; Yang M
Proteins; 2020 Nov; 88(11):1401-1412. PubMed ID: 32519403
[TBL] [Abstract][Full Text] [Related]
2. Specificity of MLL1 and TET3 CXXC domains towards naturally occurring cytosine modifications.
Stroynowska-Czerwinska A; Piasecka A; Bochtler M
Biochim Biophys Acta Gene Regul Mech; 2018 Dec; 1861(12):1093-1101. PubMed ID: 30352306
[TBL] [Abstract][Full Text] [Related]
3. Automethylation activities within the mixed lineage leukemia-1 (MLL1) core complex reveal evidence supporting a "two-active site" model for multiple histone H3 lysine 4 methylation.
Patel A; Vought VE; Swatkoski S; Viggiano S; Howard B; Dharmarajan V; Monteith KE; Kupakuwana G; Namitz KE; Shinsky SA; Cotter RJ; Cosgrove MS
J Biol Chem; 2014 Jan; 289(2):868-84. PubMed ID: 24235145
[TBL] [Abstract][Full Text] [Related]
4. Functional specificity of CpG DNA-binding CXXC domains in mixed lineage leukemia.
Risner LE; Kuntimaddi A; Lokken AA; Achille NJ; Birch NW; Schoenfelt K; Bushweller JH; Zeleznik-Le NJ
J Biol Chem; 2013 Oct; 288(41):29901-10. PubMed ID: 23990460
[TBL] [Abstract][Full Text] [Related]
5. Solution structure of the nonmethyl-CpG-binding CXXC domain of the leukaemia-associated MLL histone methyltransferase.
Allen MD; Grummitt CG; Hilcenko C; Min SY; Tonkin LM; Johnson CM; Freund SM; Bycroft M; Warren AJ
EMBO J; 2006 Oct; 25(19):4503-12. PubMed ID: 16990798
[TBL] [Abstract][Full Text] [Related]
6. A non-active-site SET domain surface crucial for the interaction of MLL1 and the RbBP5/Ash2L heterodimer within MLL family core complexes.
Shinsky SA; Hu M; Vought VE; Ng SB; Bamshad MJ; Shendure J; Cosgrove MS
J Mol Biol; 2014 Jun; 426(12):2283-99. PubMed ID: 24680668
[TBL] [Abstract][Full Text] [Related]
7. Binding to nonmethylated CpG DNA is essential for target recognition, transactivation, and myeloid transformation by an MLL oncoprotein.
Ayton PM; Chen EH; Cleary ML
Mol Cell Biol; 2004 Dec; 24(23):10470-8. PubMed ID: 15542854
[TBL] [Abstract][Full Text] [Related]
8. Cyp33 binds AU-rich RNA motifs via an extended interface that competitively disrupts the gene repressive Cyp33-MLL1 interaction in vitro.
Lloyd NR; Wuttke DS
PLoS One; 2021; 16(2):e0237956. PubMed ID: 33606679
[TBL] [Abstract][Full Text] [Related]
9. DNA Sequence Recognition of Human CXXC Domains and Their Structural Determinants.
Xu C; Liu K; Lei M; Yang A; Li Y; Hughes TR; Min J
Structure; 2018 Jan; 26(1):85-95.e3. PubMed ID: 29276034
[TBL] [Abstract][Full Text] [Related]
10. Discovery of MLL1 binding units, their localization to CpG Islands, and their potential function in mitotic chromatin.
Bina M; Wyss P; Novorolsky E; Zulkelfi N; Xue J; Price R; Fay M; Gutmann Z; Fogler B; Wang D
BMC Genomics; 2013 Dec; 14():927. PubMed ID: 24373511
[TBL] [Abstract][Full Text] [Related]
11. Structure of the MLL CXXC domain-DNA complex and its functional role in MLL-AF9 leukemia.
Cierpicki T; Risner LE; Grembecka J; Lukasik SM; Popovic R; Omonkowska M; Shultis DD; Zeleznik-Le NJ; Bushweller JH
Nat Struct Mol Biol; 2010 Jan; 17(1):62-8. PubMed ID: 20010842
[TBL] [Abstract][Full Text] [Related]
12. The internal interaction in RBBP5 regulates assembly and activity of MLL1 methyltransferase complex.
Han J; Li T; Li Y; Li M; Wang X; Peng C; Su C; Li N; Li Y; Xu Y; Chen Y
Nucleic Acids Res; 2019 Nov; 47(19):10426-10438. PubMed ID: 31544921
[TBL] [Abstract][Full Text] [Related]
13. RNA binding induces an allosteric switch in Cyp33 to repress MLL1-mediated transcription.
Blatter M; Meylan C; Cléry A; Giambruno R; Nikolaev Y; Heidecker M; Solanki JA; Diaz MO; Gabellini D; Allain FH
Sci Adv; 2023 Apr; 9(16):eadf5330. PubMed ID: 37075125
[TBL] [Abstract][Full Text] [Related]
14. Somatic cancer mutations in the MLL1 histone methyltransferase modulate its enzymatic activity and dependence on the WDR5/RBBP5/ASH2L complex.
Weirich S; Kudithipudi S; Jeltsch A
Mol Oncol; 2017 Apr; 11(4):373-387. PubMed ID: 28182322
[TBL] [Abstract][Full Text] [Related]
15. Alterations of the CxxC domain preclude oncogenic activation of mixed-lineage leukemia 2.
Bach C; Mueller D; Buhl S; Garcia-Cuellar MP; Slany RK
Oncogene; 2009 Feb; 28(6):815-23. PubMed ID: 19060922
[TBL] [Abstract][Full Text] [Related]
16. The MLL1 trimeric catalytic complex is a dynamic conformational ensemble stabilized by multiple weak interactions.
Kaustov L; Lemak A; Wu H; Faini M; Fan L; Fang X; Zeng H; Duan S; Allali-Hassani A; Li F; Wei Y; Vedadi M; Aebersold R; Wang Y; Houliston S; Arrowsmith CH
Nucleic Acids Res; 2019 Sep; 47(17):9433-9447. PubMed ID: 31400120
[TBL] [Abstract][Full Text] [Related]
17. Targeting MLL1 H3K4 methyltransferase activity in mixed-lineage leukemia.
Cao F; Townsend EC; Karatas H; Xu J; Li L; Lee S; Liu L; Chen Y; Ouillette P; Zhu J; Hess JL; Atadja P; Lei M; Qin ZS; Malek S; Wang S; Dou Y
Mol Cell; 2014 Jan; 53(2):247-61. PubMed ID: 24389101
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the binding of mixed lineage leukemia 1 (MLL1) and histone 3 peptides to WD repeat domain 5 (WDR5) for the design of inhibitors of the MLL1-WDR5 interaction.
Karatas H; Townsend EC; Bernard D; Dou Y; Wang S
J Med Chem; 2010 Jul; 53(14):5179-85. PubMed ID: 20575550
[TBL] [Abstract][Full Text] [Related]
19. Structure of WDR5 bound to mixed lineage leukemia protein-1 peptide.
Patel A; Dharmarajan V; Cosgrove MS
J Biol Chem; 2008 Nov; 283(47):32158-61. PubMed ID: 18829459
[TBL] [Abstract][Full Text] [Related]
20. Structural basis of nucleosome recognition and modification by MLL methyltransferases.
Xue H; Yao T; Cao M; Zhu G; Li Y; Yuan G; Chen Y; Lei M; Huang J
Nature; 2019 Sep; 573(7774):445-449. PubMed ID: 31485071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]